RNA m¹A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stability and is a potential therapeutic target

Abstract

Background: The role of N1-methyladenosine (m¹A) in cancer is poorly understood. Here we explored the function of RNA methyltransferase TRNA methyltransferase 61A (TRMT61A) in colorectal cancer (CRC) and its potential as a therapeutic target.

Methods: RNA m¹A levels were assessed through liquid chromatography-mass spectrometry. The expression and clinical significance of TRMT61A were investigated across five human CRC cohorts. The function of TRMT61A was elucidated using CRC cell lines, patient-derived organoids, xenografts, and transgenic mouse models. Integrated analyses of m¹A-sequencing and RNA-sequencing revealed the underlying mechanisms of TRMT61A. A nanoparticle-based small interfering RNA (siRNA) delivery system and a specific inhibitor were developed to target TRMT61A. The efficacy and safety of targeting TRMT61A were assessed.

Results: Our research revealed a consistent increase in TRMT61A expression and total RNA m¹A levels within primary CRCs. High TRMT61A expression was associated with poor prognosis of CRC patients. Through CRISPR/Cas9 screenings, we identified TRMT61A as the most essential gene among m¹A regulators. Furthermore, we established that TRMT61A promoted CRC tumorigenesis and progression by enhancing the mRNA stability of critical targets in an m¹A-dependent manner. In particular, TRMT61A boosted the mRNA stability of one cut homeobox 2 (ONECUT2), which in turn triggered son of sevenless homolog 1 (SOS1) transcription, leading to the induction of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling in CRC. Notably, our study underscored the safety and substantial anti-CRC effects achievable by inhibiting TRMT61A using nanoparticle-encapsulated siTRMT61A or our newly discovered small molecule compound, pentagalloylglucose.

Conclusions: Our study unveiled the tumor-promoting role of TRMT61A in CRC via the m¹A-ONECUT2-SOS1-MAPK/ERK pathway. Targeting TRMT61A showed promise as a therapeutic strategy for treating CRC.

Keywords

Colorectal Cancer / Therapeutic target / TRMT61A / MAPK/ERK / N¹-Methyladenosine

References

[1] Liu Z, Guo C, Dang Q, Wang L, Liu L, Weng S, et al. Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer. EBioMedicine. 2022;75:103750.

[2] Zhou J, Foroughi Pour A, Deirawan H, Daaboul F, Aung TN, Beydoun R, et al. Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality. EBioMedicine. 2023;94:104726.

[3] Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA Modifications in Gene Expression Regulation. Cell. 2017;169(7):1187-200.

[4] Niu X, Yang Y, Ren Y, Zhou S, Mao Q, Wang Y. Crosstalk between m(6)A regulators and mRNA during cancer progression. Oncogene. 2022;41(39):4407-19.

[5] Chen H, Zhang X, Su H, Zeng J, Chan H, Li Q, et al. Immune dysregulation and RNA N6-methyladenosine modification in sepsis. Wiley Interdiscip Rev RNAr. 2022:e1764.

[6] Su H, Cheung H, Lau HC, Chen H, Zhang X, Qin N, et al. Crosstalk between gut microbiota and RNA N6-methyladenosine modification in cancer. FEMS Microbiol Rev. 2023;47(4): fuad036.

[7] Motorin Y, Helm M. RNA nucleotide methylation: 2021 update. Wiley Interdiscip Rev RNA. 2022;13(1):e1691.

[8] Cayir A. RNA modifications as emerging therapeutic targets. Wiley Interdiscip Rev RNA. 2022;13(4):e1702.

[9] El Yacoubi B, Bailly M, de Crecy-Lagard V. Biosynthesis and function of posttranscriptional modifications of transfer RNAs. Annu Rev Genet. 2012;46:69-95.

[10] Sharma S, Watzinger P, Kotter P, Entian KD. Identification of a novel methyltransferase, Bmt2, responsible for the N-1-methyl-adenosine base modification of 25S rRNA in Saccharomyces cerevisiae. Nucleic Acids Res. 2013;41(10):5428-43.

[11] Li X, Xiong X, Zhang M, Wang K, Chen Y, Zhou J, et al. Base-Resolution Mapping Reveals Distinct m(1)A Methylome in Nuclear- and Mitochondrial-Encoded Transcripts. Mol Cell. 2017;68(5):993-1005.e9.

[12] Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D, et al. The m¹A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017;551(7679):251-5.

[13] Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, Ben-Haim MS, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature. 2016;530(7591):441-6.

[14] Li X, Xiong X, Wang K, Wang L, Shu X, Ma S, et al. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. Nat Chem Biol. 2016;12(5):311-6.

[15] Zhou H, Kimsey IJ, Nikolova EN, Sathyamoorthy B, Grazioli G, McSally J, et al. m(1)A and m(1)G disrupt A-RNA structure through the intrinsic instability of Hoogsteen base pairs. Nat Struct Mol Biol. 2016;23(9):803-10.

[16] Dai X, Wang T, Gonzalez G, Wang Y. Identification of YTH Domain-Containing Proteins as the Readers for N1-Methyladenosine in RNA. Anal Chem. 2018;90(11):6380-4.

[17] Chen Z, Qi M, Shen B, Luo G, Wu Y, Li J, et al. Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res. 2019;47(5):2533-45.

[18] Chujo T, Suzuki T. Trmt61B is a methyltransferase responsible for 1-methyladenosine at position 58 of human mitochondrial tRNAs. RNA. 2012;18(12):2269-76.

[19] Engel M, Chen A. The emerging role of mRNA methylation in normal and pathological behavior. Genes Brain Behav. 2018;17(3):e12428.

[20] Komal S, Zhang LR, Han SN. Potential regulatory role of epigenetic RNA methylation in cardiovascular diseases. Biomed Pharmacother. 2021;137:111376.

[21] Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, et al. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat Commun. 2021;12(1):6314.

[22] Su Z, Monshaugen I, Wilson B, Wang F, Klungland A, Ougland R, et al. TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer. Nat Commun. 2022;13(1):2165.

[23] Tang J, Chen H, Wong CC, Liu D, Li T, Wang X, et al. DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients. Oncogene. 2018;37(22):3006-21.

[24] Kurozumi S, Yamaguchi Y, Hayashi S, Hiyoshi H, Suda T, Gohno T, et al. Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. Cancer Med. 2016;5(8):1873-82.

[25] Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014;20(1):29-36.

[26] Chen H, Gao S, Liu W, Wong CC, Wu J, Wu J, et al. RNA N(6)-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m(6)A-GLUT1-mTORC1 Axis and Is a Therapeutic Target. Gastroenterology. 2021;160(4):1284-300.e16.

[27] Langmead B, Trapnell C, Pop M, Salzberg SL.Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10(3):R25.

[28] Li W, Xu H, Xiao TF, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15(12):554.

[29] Chen H, Wong CC, Liu D, Go MYY, Wu B, Peng S, et al. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Theranostics. 2019;9(18):5246-60.

[30] Qian Y, Wong CC, Xu J, Chen H, Zhang Y, Kang W, et al. Sodium Channel Subunit SCNN1B Suppresses Gastric Cancer Growth and Metastasis via GRP78 Degradation. Cancer Res. 2017;77(8):1968-82.

[31] Li W, Wong CC, Zhang X, Kang W, Nakatsu G, Zhao Q, et al. CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1alpha axis to inhibit gastric tumorigenesis. Oncogene. 2018;37(50):6383-98.

[32] Sato T, Stange DE, Ferrante M, Vries RGJ, van Es JH, van den Brink S, et al. Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium. Gastroenterology. 2011;141(5):1762-72.

[33] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50.

[34] Tan KT, Ding LW, Wu CS, Tenen DG, Yang H. Repurposing RNA sequencing for discovery of RNA modifications in clinical cohorts. Sci Adv. 2021;7(32): eabd2605.

[35] Zhou H, Rauch S, Dai Q, Cui X, Zhang Z, Nachtergaele S, et al. Evolution of a reverse transcriptase to map N(1)-methyladenosine in human messenger RNA. Nat Methods. 2019;16(12):1281-8.

[36] Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, Berhanu Lemma R, Turchi L, Blanc-Mathieu R, et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2022;50(D1):D165-D173.

[37] Finer-Moore J, Czudnochowski N, O'Connell JD, 3rd, Wang AL, Stroud RM. Crystal Structure of the Human tRNA m(1)A58 Methyltransferase-tRNA(3)(Lys) Complex: Refolding of Substrate tRNA Allows Access to the Methylation Target. J Mol Biol. 2015;427(24):3862-76.

[38] Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A. 2009;106(51):21984-9.

[39] Chen H, Pan Y, Zhou Q, Liang C, Wong CC, Zhou Y, et al. METTL3 Inhibits Antitumor Immunity by Targeting m(6)A-BHLHE41-CXCL1/CXCR2 Axis to Promote Colorectal Cancer. Gastroenterology. 2022;163(4):891-907.

[40] Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252-9.

[41] Yan H, Zhang L, Cui X, Zheng S, Li R. Roles and mechanisms of the m(6)A reader YTHDC1 in biological processes and diseases. Cell Death Discov. 2022;8(1):237.

[42] Zhang X, Su H, Chen H, Li Q, Liu X, Zhang L, et al. RNA Modifications in Gastrointestinal Cancer: Current Status and Future Perspectives. Biomedicines. 2022;10(8):1918.

[43] Rezvantalab S, Drude NI, Moraveji MK, Guvener N, Koons EK, Shi Y, et al. PLGA-Based Nanoparticles in Cancer Treatment. Front Pharmacol. 2018;9:1260.

[44] Zhang C, Jia G. Reversible RNA Modification N(1)-methyladenosine (m(1)A) in mRNA and tRNA. Genomics Proteomics Bioinformatics. 2018;16(3):155-61.

[45] Li B, Wang F, Liu NT, Shen W, Huang T. Astragaloside IV inhibits progression of glioma via blocking MAPK/ERK signaling pathway. Biochem Biophys Res Commun. 2017;491(1):98-103.

[46] Coetzee AS, Carter EP, Rodriguez-Fernandez L, Heward J, Wang Q, Karim SA, et al. Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1. Oncogene. 2023;42(7):491-500.

[47] Saglam ASY, Alp E, Elmazoglu Z, Menevse ES. Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells. Oncol Lett. 2016;12(4):2463-74.

[48] Hu H, Dong Z, Wang X, Bai L, Lei Q, Yang J, et al. Dehydrocorydaline inhibits cell proliferation, migration and invasion via suppressing MEK1/2-ERK1/2 cascade in melanoma. Onco Targets Ther. 2019;12:5163-75.

[49] Jacquemin P, Lannoy VJ, Rousseau GG, Lemaigre FP. OC-2, a novel mammalian member of the ONECUT class of homeodomain transcription factors whose function in liver partially overlaps with that of hepatocyte nuclear factor-6. J Biol Chem. 1999;274(5):2665-71.

[50] Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, et al. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015;21(13):3061-70.

[51] Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, et al. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med. 2018;24(12):1887-98.

[52] Zhang J, Cheng J, Zeng Z, Wang Y, Li X, Xie Q, et al. Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. Oncotarget. 2015;6(39):42040-52.

[53] Ma Q, Wu K, Li H, Li H, Zhu Y, Hu G, et al. ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression. Sci Rep. 2019;9(1):20021.

[54] Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6(5):322-7.

[55] Kamioka Y, Yasuda S, Fujita Y, Aoki K, Matsuda M. Multiple decisive phosphorylation sites for the negative feedback regulation of SOS1 via ERK. J Biol Chem. 2010;285(43):33540-8.

[56] Boykevisch S, Zhao C, Sondermann H, Philippidou P, Halegoua S, Kuriyan J, et al. Regulation of ras signaling dynamics by Sos-mediated positive feedback. Curr Biol. 2006;16(21):2173-9.

[57] Das J, Ho M, Zikherman J, Govern C, Yang M, Weiss A, et al. Digital signaling and hysteresis characterize ras activation in lymphoid cells. Cell. 2009;136(2):337-51.

[58] Zeng J, Han JC, Liu ZR, Yu M, Li H, Yu JZ. Pentagalloylglucose disrupts the PALB2-BRCA2 interaction and potentiates tumor sensitivity to PARP inhibitor and radiotherapy. Cancer Lett. 2022;546:215851.

[59] Chen X, Daniels NA, Cottrill D, Cao Y, Wang X, Li Y, et al. Natural Compound alpha-PGG and Its Synthetic Derivative 6Cl-TGQ Alter Insulin Secretion: Evidence for Diminishing Glucose Uptake as a Mechanism. Diabetes Metab Syndr Obes. 2021;14:759-72.

[60] Kantapan J, Dechsupa N, Tippanya D, Nobnop W, Chitapanarux I. Gallotannin from Bouea macrophylla Seed Extract Suppresses Cancer Stem-like Cells and Radiosensitizes Head and Neck Cancer. Int J Mol Sci. 2021;22(17):9253.

[61] Meng J, Li Q, Cao Z, Gu D, Wang Y, Zhang Y, et al. Rapid screening and separation of active compounds against alpha-amylase from Toona sinensis by ligand fishing and high-speed counter-current chromatography. Int J Biol Macromol. 2021;174:270-7.

[62] Chai Y, Lee HJ, Shaik AA, Nkhata K, Xing C, Zhang J, et al. Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth. Breast Cancer Res. 2010;12(5):R67.

[63] Deiab S, Mazzio E, Eyunni S, McTier O, Mateeva N, Elshami F, et al. 1,2,3,4,6-Penta-O-galloylglucose within Galla Chinensis Inhibits Human LDH-A and Attenuates Cell Proliferation in MDA-MB-231 Breast Cancer Cells. Evid Based Complement Alternat Med. 2015;2015:276946.

[64] Mendonca P, Alghamdi S, Messeha S, Soliman KFA. Pentagalloyl glucose inhibits TNF-alpha-activated CXCL1/GRO-alpha expression and induces apoptosis-related genes in triple-negative breast cancer cells. Sci Rep. 2021;11(1):5649.

[65] Zhao W, Wang Y, Hao W, Zhao M, Peng S. In vitro inhibition of fatty acid synthase by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose plays a vital role in anti-tumour activity. Biochem Biophys Res Commun. 2014;445(2):346-51.

[66] Chen RH, Yang LJ, Hamdoun S, Chung SK, Lam CW, Zhang KX, et al. 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection. Front Pharmacol. 2021;12:634176.

[67] Ryu HG, Jeong SJ, Kwon HY, Lee HJ, Lee EO, Lee MH, et al. Penta-O-galloyl-beta-D-glucose attenuates cisplatin-induced nephrotoxicity via reactive oxygen species reduction in renal epithelial cells and enhances antitumor activity in Caki-2 renal cancer cells. Toxicol In Vitro. 2012;26(2):206-14.

[68] Li L, Shaik AA, Zhang J, Nhkata K, Wang L, Zhang Y, et al. Preparation of penta-O-galloyl-beta-D-glucose from tannic acid and plasma pharmacokinetic analyses by liquid-liquid extraction and reverse-phase HPLC. J Pharm Biomed Anal. 2011;54(3):545-50.

[69] Lin MH, Chang FR, Hua MY, Wu YC, Liu ST. Inhibitory effects of 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose on biofilm formation by Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(3):1021-7.

RIGHTS & PERMISSIONS

2025 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.